Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial)

BACKGROUND AND OBJECTIVES: This trial explores whether intravenous iron isomaltoside 1000 (Monofer®) results in a better regeneration of haemoglobin levels and prevents anaemia compared to placebo in preoperative non-anaemic patients undergoing cardiac surgery. STUDY DESIGN AND METHODS: The trial is...

Full description

Bibliographic Details
Main Authors: Johansson, P I, Rasmussen, A S, Thomsen, L L
Format: Online Article Text
Language:English
Published: John Wiley & Sons, Ltd 2015
Subjects:
Transfusion Medicine and New Therapies
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690506/
https://www.ncbi.nlm.nih.gov/pubmed/25900643
http://dx.doi.org/10.1111/vox.12278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690506/
https://www.ncbi.nlm.nih.gov/pubmed/25900643
http://dx.doi.org/10.1111/vox.12278

Similar Items